Furthermore, recent studies suggest that additional gene mutations such as BRAF mutations, PIK3CA mutations, and HER2 amplification are implicated in resistance to EGFR-targeted drugs for CRC patients with wild type KRAS [5,9]. This evidence concerns the gene BRAF and colorectal carcinoma.